MediciNova has been granted a patent for compositions and methods using ibudilast to treat progressive neurodegenerative diseases. The patent claims a method to reduce disability progression in patients with progressive multiple sclerosis by administering ibudilast. GlobalData’s report on MediciNova gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MediciNova, Peptide pharmacophores was a key innovation area identified from patents. MediciNova's grant share as of May 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of progressive neurodegenerative diseases with ibudilast
A recently granted patent (Publication Number: US11944607B2) discloses a method for reducing the likelihood of disability progression in patients diagnosed with progressive forms of multiple sclerosis. The method involves administering ibudilast or a pharmaceutically acceptable salt thereof in a therapeutically effective amount. The administration of ibudilast is specified to be for at least six months, with options for longer durations up to two years. The dosage ranges from 30 mg to 240 mg daily, administered orally at least once a day. This method is particularly targeted towards patients with primary progressive or secondary progressive multiple sclerosis, beyond the relapse-remitting stage.
Additionally, the patent also covers a method for treating Parkinson's disease by administering ibudilast or its salt to patients in need. Similar to the multiple sclerosis treatment method, the administration of ibudilast for Parkinson's disease is recommended for at least six months, with options for longer durations up to two years. The dosage ranges from 30 mg to 240 mg daily, administered orally at least once a day. This method provides a potential therapeutic approach for patients suffering from Parkinson's disease, highlighting the versatility of ibudilast in treating neurodegenerative conditions.
To know more about GlobalData’s detailed insights on MediciNova, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
